Pioneering a paradigm shift for ‘selective’ neural electrical stimulation
Restoring hand grasp movements in patients with complete tetraplegia will be the first application of Neurinnov’s technology platform.
Minimising side effects
The key to Neurinnov’s success is its ability to master selective stimulation. The company’s broad technology platform can stimulate specific nerves to restore or modulate functions, while minimising undesired activation. The reduction of side effects, which often arise from non-selective stimulation, demonstrates the true value of this technology.
An embedded Application-Specific Integrated Circuit (ASIC), which is crucial for achieving selective stimulation and guiding nerve stimulation
A casing that surrounds the neurostimulator, to which electrodes are connected
A controller that connects to the implant via an external antenna. Wireless power and data communication with the implanted device will be enabled by transcutaneous energy transfer
Software with advanced interfaces designed to simplify the tuning of the neuroprosthesis. Given the complexity of hand biomechanics and the counterintuitive nature of selective stimulation, the software incorporates powerful algorithms to overcome these challenges
An intuitive patient interface, allowing the user to control the entire system discreetly. Preliminary tests with patients showed a short learning curve and high efficiency
Our implantable neurostimulator is specifically designed for patients with complete tetraplegia who are ineligible for tendon transfer or orthopaedic surgery, the only treatment options currently available.
Neurinnov’s goal is to provide these patients with an implant that enables them to control hand movements using one of five modalities to operate the neurostimulator device. Patients will have the ability to open their hand using:
Two patients with complete tetraplegia – paralysed from the shoulders down – were able to grasp objects and perform everyday tasks, such as holding a can or eating with a fork, thanks to a neurostimulation device developed by Neurinnov. This breakthrough was achieved as part of the AGILIS study, led by INRIA.
A strong network of partners is essential for pushing the boundaries of innovation. Together, we explore new and improved approaches that drive technological advancements in neurostimulation delivering real benefits to underserved medical populations.
Contact
Phone: +33 (0)4 34 34 80 28
Email: contact@neurinnov.com